Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease.

Twenty-three patients with bone disease and chronic renal failure were treated for periods of 4--28 months with 1alpha-hydroxyvitamin D3 (1alpha-OHD3). Improvements in bone histology were consistently seen in patients with features both of osteitis fibrosa and osteomalacia but were not invariably ob...

Full description

Bibliographic Details
Main Authors: Kanis, J, Russell, R, Naik, R, Earnshaw, M, Smith, R, Heynen, G, Woods, C
Format: Journal article
Language:English
Published: 1977